Follow the people · Insider
Jeffrey S. Heier
Jeffrey S. Heier files insider transactions with the SEC as a chief scientific officer of Ocular Therapeutix (OCUL). We hold 3 disclosed purchases and sales filed since 15 September 2015, 1 of them in the last 90 days.
- Files forOCUL
- Disclosed buys and sells3 in all, 1 in the last 90 days
- Last disclosure26 August 2026
Positions held
1 post we hold — a term names its own dates; a run of filings only says when they filed- Filed 11 September 2015 — 24 August 2026Chief Scientific Officer · Ocular Therapeutix (OCUL)31 Form 4 lines · source: SEC Form 4
Everything they disclosed
31 entries, newest first — one per disclosure report, one per Form 4 line- ▼ sold on the open market 3,296 shares of Ocular TherapeutixSEC Form 426 August 2026Common Stock · traded 24 August 2026 · filed 26 August 2026
- ▼ sold on the open market 3,018 shares of Ocular TherapeutixSEC Form 428 May 2026Common Stock · traded 26 May 2026 · filed 28 May 2026
- ▼ sold on the open market 3,057 shares of Ocular TherapeutixSEC Form 425 February 2026Common Stock · traded 23 February 2026 · filed 25 February 2026
- ▼ sold on the open market 3,057 shares of Ocular TherapeutixSEC Form 425 February 2026Common Stock · traded 23 February 2026 · filed 25 February 2026
- was granted 79,112 shares of Ocular TherapeutixSEC Form 46 January 2026Common Stock · traded 2 January 2026 · filed 6 January 2026
- was granted 240,932 shares of Ocular Therapeutix (a derivative holding)SEC Form 46 January 2026Stock Option (Right to Buy) · traded 2 January 2026 · filed 6 January 2026
- was granted 240,932 shares of Ocular Therapeutix (a derivative holding)SEC Form 46 January 2026Stock Option (Right to Buy) · traded 2 January 2026 · filed 6 January 2026
- was granted 79,112 shares of Ocular TherapeutixSEC Form 46 January 2026Common Stock · traded 2 January 2026 · filed 6 January 2026
- ▼ sold on the open market 3,469 shares of Ocular TherapeutixSEC Form 426 November 2025Common Stock · traded 24 November 2025 · filed 26 November 2025
- ▼ sold on the open market 10,502 shares of Ocular TherapeutixSEC Form 46 October 2025Common Stock · traded 2 October 2025 · filed 6 October 2025
- ▼ sold on the open market 3,063 shares of Ocular TherapeutixSEC Form 427 August 2025Common Stock · traded 25 August 2025 · filed 27 August 2025
- ▼ sold on the open market 3,024 shares of Ocular TherapeutixSEC Form 427 May 2025Common Stock · traded 23 May 2025 · filed 27 May 2025
- ▼ sold on the open market 3,061 shares of Ocular TherapeutixSEC Form 426 February 2025Common Stock · traded 24 February 2025 · filed 26 February 2025
- ▼ sold on the open market 2,948 shares of Ocular TherapeutixSEC Form 427 November 2024Common Stock · traded 25 November 2024 · filed 27 November 2024
- was granted 200,000 shares of Ocular Therapeutix (a derivative holding)SEC Form 44 October 2024Stock Option (Right to Buy) · traded 2 October 2024 · filed 4 October 2024
- was granted 100,000 shares of Ocular TherapeutixSEC Form 44 October 2024Common Stock · traded 2 October 2024 · filed 4 October 2024
- was granted 17,350 shares of Ocular Therapeutix (a derivative holding)SEC Form 418 August 2023Stock Option (Right to Buy) · traded 2 August 2023 · filed 18 August 2023
- was granted 36,000 shares of Ocular Therapeutix (a derivative holding)SEC Form 416 June 2023Stock Option (Right to Buy) · traded 14 June 2023 · filed 16 June 2023
- was granted 12,000 shares of Ocular TherapeutixSEC Form 416 June 2023Common Stock · traded 14 June 2023 · filed 16 June 2023
- was granted 16,000 shares of Ocular Therapeutix (a derivative holding)SEC Form 418 October 2022Stock Option (Right to Buy) · traded 17 October 2022 · filed 18 October 2022
- was granted 26,800 shares of Ocular Therapeutix (a derivative holding)SEC Form 421 June 2022Stock Option (Right to Buy) · traded 16 June 2022 · filed 21 June 2022
- was granted 8,933 shares of Ocular TherapeutixSEC Form 421 June 2022Common Stock · traded 16 June 2022 · filed 21 June 2022
- ▲ bought on the open market 15,000 shares of Ocular TherapeutixSEC Form 416 May 2022Common Stock · traded 12 May 2022 · filed 16 May 2022
- was granted 18,000 shares of Ocular Therapeutix (a derivative holding)SEC Form 422 June 2021Stock Option (Right to Buy) · traded 18 June 2021 · filed 22 June 2021
- was granted 18,000 shares of Ocular Therapeutix (a derivative holding)SEC Form 426 June 2020Stock Option (Right to Buy) · traded 25 June 2020 · filed 26 June 2020
- was granted 18,000 shares of Ocular Therapeutix (a derivative holding)SEC Form 413 June 2019Stock Option (Right to Buy) · traded 11 June 2019 · filed 13 June 2019
- ▲ bought on the open market 24,000 shares of Ocular TherapeutixSEC Form 418 March 2019Common Stock · traded 15 March 2019 · filed 18 March 2019
- was granted 18,000 shares of Ocular Therapeutix (a derivative holding)SEC Form 415 June 2018Stock Option (Right to Buy) · traded 14 June 2018 · filed 15 June 2018
- was granted 13,500 shares of Ocular Therapeutix (a derivative holding)SEC Form 41 June 2017Stock Option (Right to Buy) · traded 1 June 2017 · filed 1 June 2017
- was granted 13,500 shares of Ocular Therapeutix (a derivative holding)SEC Form 43 June 2016Stock Option (Right to Buy) · traded 2 June 2016 · filed 3 June 2016
- was granted 11,363 shares of Ocular Therapeutix (a derivative holding)SEC Form 415 September 2015Stock Option (Right to Buy) · traded 11 September 2015 · filed 15 September 2015
Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.